Knockdown of Tousled‑like kinase 1 inhibits survival of glioblastoma multiforme cells.
Animals
Blotting, Western
Cell Cycle
/ genetics
Cell Line, Tumor
Cell Survival
/ genetics
Female
Gene Expression Regulation, Neoplastic
/ genetics
Glioblastoma
/ genetics
Humans
Mice
Mice, Nude
Open Reading Frames
/ genetics
Protein Serine-Threonine Kinases
/ genetics
RNA, Small Interfering
/ genetics
Reverse Transcriptase Polymerase Chain Reaction
Xenograft Model Antitumor Assays
Journal
International journal of molecular medicine
ISSN: 1791-244X
Titre abrégé: Int J Mol Med
Pays: Greece
ID NLM: 9810955
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
13
05
2019
accepted:
17
01
2020
pubmed:
30
5
2020
medline:
9
3
2021
entrez:
30
5
2020
Statut:
ppublish
Résumé
Glioblastoma multiforme (GBM) is an aggressive type of brain tumour that commonly exhibits resistance to treatment. The tumour is highly heterogenous and complex kinomic alterations have been reported leading to dysregulation of signalling pathways. The present study aimed to investigate the novel kinome pathways and to identify potential therapeutic targets in GBM. Meta‑analysis using Oncomine identified 113 upregulated kinases in GBM. RNAi screening was performed on identified kinases using ON‑TARGETplus siRNA library on LN18 and U87MG. Tousled‑like kinase 1 (TLK1), which is a serine/threonine kinase was identified as a potential hit. In vitro functional validation was performed as the role of TLK1 in GBM is unknown. TLK1 knockdown in GBM cells significantly decreased cell viability, clonogenicity, proliferation and induced apoptosis. TLK1 knockdown also chemosensitised the GBM cells to the sublethal dose of temozolomide. The downstream pathways of TLK1 were examined using microarray analysis, which identified the involvement of DNA replication, cell cycle and focal adhesion signalling pathways. In vivo validation of the subcutaneous xenografts of stably transfected sh‑TLK1 U87MG cells demonstrated significantly decreased tumour growth in female BALB/c nude mice. Together, these results suggested that TLK1 may serve a role in GBM survival and may serve as a potential target for glioma.
Identifiants
pubmed: 32468002
doi: 10.3892/ijmm.2020.4619
pmc: PMC7307829
doi:
Substances chimiques
RNA, Small Interfering
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
TLK1 protein, human
EC 2.7.11.1
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
685-699Références
Cell Death Differ. 2016 Jan;23(1):146-57
pubmed: 26088162
J Biol Chem. 2001 Jun 1;276(22):19656-63
pubmed: 11278572
Blood. 2001 Sep 15;98(6):1752-9
pubmed: 11535508
Cancer Res. 2005 May 15;65(10):4088-96
pubmed: 15899798
Prog Nucleic Acid Res Mol Biol. 2001;65:101-27
pubmed: 11008486
Cancer Res. 2009 Oct 1;69(19):7548-56
pubmed: 19773446
Cancer Res. 2005 Aug 15;65(16):7194-204
pubmed: 16103070
J Biomol Screen. 2008 Feb;13(2):149-58
pubmed: 18216396
Nature. 2007 Mar 8;446(7132):153-8
pubmed: 17344846
Science. 2002 Dec 6;298(5600):1912-34
pubmed: 12471243
Clin Cancer Res. 2002 Nov;8(11):3311-4
pubmed: 12429616
Curr Mol Pharmacol. 2012 Jan;5(1):102-14
pubmed: 22122467
Cell Death Differ. 2017 Nov;24(11):1872-1885
pubmed: 28708136
Cancer Discov. 2012 May;2(5):458-71
pubmed: 22588883
Neuro Oncol. 2008 Feb;10(1):19-31
pubmed: 18079358
Cancer Lett. 2015 Jun 28;362(1):1-7
pubmed: 25796440
BMC Genomics. 2008 Jul 24;9:348
pubmed: 18652687
Cell. 1993 Dec 3;75(5):939-50
pubmed: 8252629
Cancer Cell. 2006 May;9(5):391-403
pubmed: 16697959
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W77-83
pubmed: 23703215
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11381-6
pubmed: 20534549
Oncogene. 2007 Jan 11;26(2):186-97
pubmed: 16819506
PLoS One. 2013;8(2):e54072
pubmed: 23457446
Oncogene. 2003 Jul 31;22(31):4918-23
pubmed: 12894235
Oncogene. 2008 Sep 18;27(41):5497-510
pubmed: 18794884
Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9
pubmed: 15827123
Nat Clin Pract Oncol. 2008 Aug;5(8):476-86
pubmed: 18542116
Clin Cancer Res. 2008 Feb 15;14(4):957-60
pubmed: 18281526
BMC Cancer. 2014 Sep 26;14:718
pubmed: 25256166
BMC Cancer. 2008 Jan 29;8:29
pubmed: 18230152
J Neurooncol. 2012 Apr;107(2):359-64
pubmed: 22045118
Am J Pathol. 2015 Jul;185(7):1820-33
pubmed: 25976245
EMBO J. 1999 Oct 15;18(20):5691-702
pubmed: 10523312
Front Oncol. 2012 Oct 31;2:157
pubmed: 23120745
J Cell Sci. 2007 Nov 1;120(Pt 21):3883-94
pubmed: 17940067
Nat Cell Biol. 2013 Jan;15(1):2-8
pubmed: 23263379
PLoS One. 2008;3(11):e3814
pubmed: 19043568
Onco Targets Ther. 2013 May 24;6:555-61
pubmed: 23737671
Oncogene. 2003 Sep 4;22(38):5927-37
pubmed: 12955071
Int J Mol Sci. 2015 Sep 03;16(9):21138-52
pubmed: 26404259
J Biomed Res. 2010 Nov;24(6):424-35
pubmed: 23554659
Mol Biol Cell. 2016 Jan 1;27(1):12-9
pubmed: 26510500
Exp Ther Med. 2012 Jan;3(1):9-14
pubmed: 22969836
Curr Biol. 2010 Apr 27;20(8):677-86
pubmed: 20381350
Oncogene. 2004 Feb 12;23(6):1283-90
pubmed: 14961077
Prostate. 2011 Sep 15;71(13):1367-73
pubmed: 21647934
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
Cancer Lett. 2010 Oct 1;296(1):27-34
pubmed: 20381954
Clin Cancer Res. 2015 Apr 15;21(8):1916-24
pubmed: 25609063
WHO Chron. 1985;39(2):51-6
pubmed: 4090462
ISRN Mol Biol. 2012 Jan 1;2012:627596
pubmed: 23869254
J Neurochem. 2006 Feb;96(3):766-76
pubmed: 16405512
PLoS One. 2014 Mar 21;9(3):e92853
pubmed: 24658335
Nucleic Acids Res. 2019 Jul 2;47(W1):W234-W241
pubmed: 30931480
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9666-70
pubmed: 11493700
Front Neurosci. 2015 Jun 16;9:218
pubmed: 26136652
Nat Methods. 2009 Aug;6(8):569-75
pubmed: 19644458
Neoplasia. 2004 Jan-Feb;6(1):1-6
pubmed: 15068665
Genes Dev. 2003 Oct 15;17(20):2578-90
pubmed: 14561777
Plant Cell. 1997 Mar;9(3):335-53
pubmed: 9090879
J Neurosurg. 2001 Sep;95(3):480-8
pubmed: 11565871
Cell Mol Life Sci. 2010 Mar;67(6):875-90
pubmed: 20012461
Oncotarget. 2018 Apr 17;9(29):20640-20657
pubmed: 29755678
EMBO J. 2003 Apr 1;22(7):1676-87
pubmed: 12660173
Genes Cancer. 2013 Jan;4(1-2):39-53
pubmed: 23946870
Cancer Cell. 2006 Apr;9(4):287-300
pubmed: 16616334
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Clin Cancer Res. 2006 Jul 1;12(13):3935-41
pubmed: 16818690
Cancer Res. 2006 Aug 15;66(16):8147-54
pubmed: 16912193
Pharmacogenomics. 2006 Apr;7(3):299-309
pubmed: 16610941
J Neurooncol. 2011 Mar;102(1):1-7
pubmed: 20593219